NATCO Pharma has said that the US Court of Appeals for the Federal Circuit ruling, has reversed a district court's finding related to Teva's US Patent for Copaxone.
This would essentially mean that NATCO could launch the generic Copaxone - through its marketing partner - Mylan Inc., during May 2014, subject to FDA approval. Copaxone (Glatiramer Acetate) is used in the treatment of relapsing-remitting multiple sclerosis.
The product is estimated to have clocked revenues, in USA, of about US $3.45 Billion during 2012.
Shares in Natco which closed at Rs 491 on Friday, may receive a boost when markets re-open for trading on Monday.
GoodReturns.in
Notifications
Settings
Clear Notifications
No New Notifications
Notifications
Use the toggle to switch on notifications
Block for 8 hours
Block for 12 hours
Block for 24 hours
Don't block
To start receiving timely alerts, as shown below click on the Green “lock” icon next to the address bar
Click it and Unblock the Notifications
Close X
Close X
To Start receiving timely alerts please follow the below steps:
Click on the Menu icon of the browser, it opens up a list of options.
Click on the “Options ”, it opens up the settings page,
Here click on the “Privacy & Security” options listed on the left hand side of the page.
Scroll down the page to the “Permission” section .
Here click on the “Settings” tab of the Notification option.
A pop up will open with all listed sites, select the option “ALLOW“, for the respective site under the status head to allow the notification.
Once the changes is done, click on the “Save Changes” option to save the changes.
Click it and Unblock the Notifications
Sign in with Google